Form 4: Voyager Therapeutics CFO Sells Shares for Tax Obligations
Insider Transaction Report
Voyager Therapeutics' Chief Financial Officer, Nathan D. Jorgensen, sold 7,666 shares of common stock to cover tax withholding obligations.
Summary
- Nathan D. Jorgensen, Chief Financial Officer of Voyager Therapeutics, Inc. (VYGR), reported a sale of common stock.
- The transaction involved the disposition of 7,666 shares of common stock on October 3, 2025.
- The shares were sold at a weighted average price of $4.78 per share, with individual sales ranging from $4.74 to $4.85.
- The sale was non-discretionary, executed pursuant to a Rule 10b5-1 plan adopted on May 9, 2025.
- The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock units.
- Following the transaction, Mr. Jorgensen beneficially owns 123,834 shares of common stock directly.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary insider stock sale for tax purposes, which is generally considered neutral in terms of company sentiment.
Positives
- The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned, non-discretionary sale for tax purposes, which enhances transparency and reduces concerns about opportunistic insider selling.
Negatives
- A reduction in direct beneficial ownership by a key executive (CFO) occurred, although it was for routine tax purposes.
Future Outlook
NA
Industry Context
This is a routine insider transaction filing (Form 4) and does not provide information related to broader industry trends or competitors. Such filings are common across all industries when executives exercise equity awards and sell shares to cover tax obligations.
Stakeholder Impact
- Shareholders: A minor, routine reduction in the Chief Financial Officer's direct beneficial ownership, which is common for tax-related sales and generally not indicative of a change in management's confidence.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date reporting person adopted a durable automatic sales instruction letter (Rule 10b5-1 plan). |
| 10/03/2025 | Date of transaction (sale of common stock) and vesting of restricted stock units. |
| 10/07/2025 | Date the Form 4 was signed. |
Keywords
Voyager Therapeutics, VYGR, Form 4, Insider Transaction, Stock Sale, CFO, 10b5-1 Plan, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.